Avenue Therapeutics, Inc. (ATXI)
ATXI Price and Sentiment
ATXI Latest news
Why Novavax, Orphazyme, Avenue Therapeutics Shares Are Moving Monday
2021-06-14 10:54Novavax, Inc. (NASDAQ: NVAX), Orphazyme A/S (NASDAQ: ORPH) and Avenue Therapeutics, Inc. (NASDAQ: ATXI) are among the biggest movers among biopharma stocks Monday. Novavax Finally Releases Phase 3 COVID-19 Results: After a protracted delay, Gaithersburg, Maryland-based Novavax reported preliminary results showing its coronavirus candidate NVX-CoV2371 met the primary endpoint of the Phase 3 PREVENT trial in the U.S. and Mexico.
Avenue Therapeutics Receives Complete Response Letter from the FDA for IV Tramadol
2021-06-14 07:00NEW YORK, June 14, 2021 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced that it has received a second Complete Response Letter (“CRL”) from the U.S. Food and Drug Administration (“FDA”) regarding its New Drug Application (“NDA”) seeking approval for IV tramadol.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Avenue Therapeutics, Inc. - ATXI
2021-04-21 22:34New York, New York--(Newsfile Corp. - April 21, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Avenue Therapeutics Inc. ("Avenue" or the "Company") (NASDAQ: ATXI). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Avenue and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Avenue Therapeutics, Inc. - ATXI
2021-04-19 22:09NEW YORK, April 19, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Avenue Therapeutics Inc. ("Avenue" or the "Company") (NASDAQ: ATXI). Such investors are advised to contact Robert S.
Avenue Therapeutics (ATXI) Sees Hammer Chart Pattern: Time to Buy?
2021-04-19 07:06Avenue Therapeutics (ATXI) has been struggling lately, but the selling pressure may be coming to an end soon
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Avenue Therapeutics, Inc. - ATXI
2021-04-13 23:30NEW YORK, April 13, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Avenue Therapeutics Inc. ("Avenue" or the "Company") (NASDAQ: ATXI). Such investors are advised to contact Robert S.
ATXI Stock: Over 15% Decrease Pre-Market Explanation
2021-04-13 08:18The stock price of Avenue Therapeutics, Inc. (Nasdaq: ATXI) fell by over 15% pre-market. This is why it happened.
Avenue Therapeutics Announces that the FDA is Still Reviewing Its NDA Resubmission for IV Tramadol
2021-04-13 06:30The FDA Has Not Provided a Decision Regarding the NDA The FDA Has Not Provided a Decision Regarding the NDA
ATXI Stock: Over 15% Increase Pre-Market Explanation
2021-04-12 05:45The stock price of Avenue Therapeutics Inc (NASDAQ: ATXI) increased by over 15% pre-market. This is why it happened.
Avenue Therapeutics Announces Publication of Real-World Data on Nonmedical Use of Tramadol in ASI-MV Network
2020-12-18 08:00NEW YORK, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (Avenue), a company focused on the development of intravenous (IV) tramadol for the U.S. market, today announced that a publication titled “Real-World Data on Nonmedical Use of Tramadol from Patients Evaluated for Substance Abuse Treatment in the NAVIPPRO Addiction Severity Index?Multimedia Version (ASI-MV®) Network” has been published in Drug Safety, a peer-reviewed international journal covering pharmacoepidemiology and pharmacovigilance. The publication can be accessed here.